Frequency of detection of molecular biomarkers in NGS-tested breast cancer patients
TissueTissueTissueTissuePlasmaPlasmaPlasmaPlasma
GeneAlterationHR+/HER2-HR-/HER2-HR+/HER2+HR-/HER2+HR+/HER2-HR-/HER2-HR+/HER2+HR-/HER2+
ERBB2Amp1.1%0.5%45.4%67.9%0.0%0.8%10.4%45.5%
CCND1Amp21.3%1.7%21.8%5.1%7.5%1.7%5.2%0.0%
MYCAmp9.3%15.5%18.5%17.9%1.3%5.8%1.3%9.1%
FGFR1Amp17.4%6.8%18.5%3.8%6.5%3.3%2.6%0.0%
PIK3CAMutation43.8%19.1%49.6%32.1%49.5%25.0%50.6%30.3%
ESR1Mutation19.4%1.2%13.4%0.0%41.7%4.2%31.2%0.0%
BRCA1Mutation1.9%7.2%0.8%3.8%5.1%5.0%2.6%9.1%
BRCA2Mutation6.7%3.6%5.9%1.3%8.8%5.8%14.3%3.0%
ERBB2Mutation3.4%1.4%11.8%6.4%9.5%1.7%15.6%12.1%
TP53Mutation42.2%94.7%51.3%93.6%65.8%96.7%68.8%93.9%
PTENMutation8.8%10.6%2.5%3.8%12.6%10.8%7.8%6.1%
PALB2Mutation1.6%1.2%0.8%0.0%0.2%0.0%0.0%0.0%
MTORMutation0.7%0.2%0.8%0.0%2.7%0.0%0.0%0.0%
ARID1AMutation9.0%4.8%12.6%2.6%11.0%11.7%7.8%3.0%
KRASMutation3.2%3.1%0.8%2.6%6.5%8.3%5.2%6.1%
AKT1Mutation6.5%3.4%2.5%1.3%7.5%6.7%1.3%0.0%
n=856n=414n=119n=78n=602n=120n=77n=33